The purpose of this study was to identify novel genetic variants influencing circulating asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) levels and to evaluate whether they have a prognostic value on cardiovascular mortality.
Introduction
Increasing evidence shows that both asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) might have independent roles in cardiovascular diseases 1 and the prediction of cardiovascular events. 2, 3 Elevated circulating SDMA levels have been reported to be associated with increased mortality in stroke patients, 4 an increased risk of cardiac death in patients with non-ST-segment elevation myocardial infarction, 5 and worse prognosis in patients referred for coronary angiography. 3 Indeed, increasing in vitro and in vivo evidence support the concept that SDMA may have an independent role in the pathogenesis of cardiovascular diseases. Symmetric dimethylarginine induces reactive oxygen species production of monocytes 6 and promotes inflammation in chronic kidney disease. 7 Moreover, recent data show that SDMA may promote endothelial dysfunction. 8 Previous candidate gene studies have identified a limited number of single-nucleotide polymorphisms (SNPs) associated with plasma ADMA levels in the dimethylarginine dimethylaminohydrolase-1 and -2 (DDAH1 and DDAH2) loci, 9 whereas the genetic variants regulating SDMA levels are not known. There is evidence that AGXT2 plays a role in both ADMA and SDMA metabolisms in vivo, 10 but association data between genetic variants and circulating methylarginine levels in humans are currently lacking. Furthermore, AGXT2 knockout mice show a hypertensive phenotype, but the underlying mechanisms behind this observation are not currently well understood. 11 To investigate the role of AGXT2 in health and disease in humans, the identification of the functional genetic variants affecting the enzymatic activity of the AGXT2 protein and the regulation of its expression in different human tissues is of major importance. Therefore, to identify additional new loci for ADMA, and especially for SDMA, we performed the first meta-analyses of genome-wide association (GWA) studies for the methylarginines using data from 5110 participants from the Young Finns Study (YFS) and the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Secondly, we fine-mapped the AGXT2 locus, that showed the strongest association with SDMA, for variants independently affecting circulating SDMA levels. Finally, we tested the association of these variants with mortality endpoints in LURIC and heart rate variability (HRV) parameters in YFS to be able to characterize the pathophysiological role of these new AGXT2 variants.
Methods
The study flow is summarized in Figure 1 .
Study populations
We conducted a meta-analysis of GWA data on 5110 individuals of European descent drawn from two large cohorts: the YFS and the LURIC study. The YFS cohort is a Finnish longitudinal population study sample on the evolution of cardiovascular risk factors from childhood to adulthood. 12 In the present study, we used the variables measured in 2001. The LURIC study consists of 3316 Caucasian patients hospitalized for coronary angiography between 1997 and 2000 at a tertiary care centre in Southwestern Germany. 13 Clinical indications for angiography were chest pain or a positive non-invasive stress test suggestive of myocardial ischaemia. To limit clinical heterogeneity, individuals suffering from acute illnesses other than acute coronary syndrome, chronic noncardiac diseases, and a history of malignancy within the 5 past years were excluded. See further description and characteristics in Supplementary material online, Methods S1 and Table S1 .
Biochemical
Asymmetric dimethylarginine and symmetric dimethylarginine were measured from frozen serum using the same reversed-phase highperformance liquid chromatography method in both studies. For Figure 1 Study population and flow. Flow diagram depicting the cohorts and numbers of participants. The associations of the AGXT2 variants identified in the conditional analysis with heart rate variability and sudden cardiac death were investigated in the Young Finns Study and Ludwigshafen Risk and Cardiovascular Health cohorts, respectively.
Genome-wide association study on dimethylarginines details and other biochemical measurements, see Supplementary material online, Methods S2.
Genotyping and quality control
In LURIC, genotyping was done by using the Affymetrix Human SNP Array 6.0 at the LURIC Study facility. In the YFS, genotyping was done using a custom-built Illumina Human 670k BeadChip at the Welcome Trust Sanger Institute (Supplementary material online, Methods S3). Genotype imputation was performed using minimac 14 
Short-term heart rate variability
We used the ratio between low-and high-frequency components (LF/ HF) of spectral HRV to estimate sympathovagal balance in the YFS participants. The mean heart rate during HRV measurement was used as an estimate of the resting heart rate. Breathing was metronome controlled at the frequency of 0.25 Hz. We excluded subjects with current antihypertensive medications, Type 1 diabetes, pregnant women, and breastfeeding women. After these exclusions, genotype data were available for 1723 subjects and were included in the association analyses. For details, see Supplementary material online, Methods S4.
Classification of SCD cases
In LURIC, sudden cardiac death (SCD) was defined as sudden unexpected death either within 1 h of symptom onset or within 24 h of having been observed alive and symptom-free. Patients who suffered from any noncardiac chronic and terminal disease (e.g. cancer), so that their death was not unexpected, and those whose sudden death was most likely attributed to a non-cardiac cause were not classified as SCD cases. See Supplementary material online, Methods S4 for more details about the cause of death classifications.
Statistical analysis
To identify and correct for population stratification, we performed an MDS analysis as implemented in PLINK 1.07. 16 In both studies, residual ADMA and SDMA concentrations or residuals of ADMA/SDMA ratio were determined after regression adjustment using the R software. Outliers (≥4 SD from the mean) were removed from the dimethylarginine phenotype values before covariate adjustment to avoid spurious associations (typically 5 -20 data points for any one outcome). Residuals were obtained using linear regression analysis in which the dimethylarginine phenotypes were adjusted for sex, age, body mass index, and serum creatinine to account for variation in renal function, as well as the first three MDS components to control for population stratification. As circulating ADMA is a major determinant of SDMA levels and vice versa, 3 the model for ADMA was additionally adjusted for SDMA and that for SDMA was adjusted for ADMA. Residuals were normalized to have a mean of 0 and SD of 1 using inverse-normal transformation. The association analysis of the imputed SNPs and indels assuming an additive genetic model was carried out utilizing the SNPTEST v2.4.1 17 and ProbABEL v. 0.3.0 18 softwares in YFS and LURIC, respectively. Quantile-quantile and Manhattan plots were drawn for the analysis of the results. To estimate how well the distribution was calibrated, for each phenotype in both studies, we calculated the genomic inflation factor (l) from all imputed variants. The l for each trait in both studies ranged from 0.993 to 1.012, suggesting that there was no major residual confounding by population stratification, and little evidence of cryptic relatedness. We created the regional association plots using LocusZoom. 19 The summary results from both cohorts were meta-analyzed with the random-effects meta-analysis method implemented in GWAMA. 20 A stringent genome-wide significance level of 1.66 × 10 28 was set to correct for multiple testing of the three phenotypes. We fine-mapped the AGXT2 locus using a series of sequential conditional analyses by adding the most strongly associated SNP into the regression model as a covariate and using the inverse-normal transformed residuals as an outcome variable to test all remaining regional SNPs for association. The results from both studies were combined using a random-effects meta-analysis. We repeated this procedure until the strongest SNP showed a conditional P-value of .10 24 .
Further statistical analyses were performed using R 3.0.0 (http://www. r-project.org). A Cox regression proportional hazards analysis was performed to test whether the AGXT2 and SLC25A45 genotypes were associated with mortality endpoints. The risk of mortality was quantified as hazard ratios (HRs). The proportional hazards assumption was checked with Schoenfeld's residuals and was met for all models. The screening tests were conducted using age and sex as covariates and an additive genetic model. Further analyses were performed adjusting for wellestablished SCD risk factors. Secondly, to investigate the possible mechanism underlying the associations with SCD, analyses were stratified according to the median value of left ventricular systolic pressure (LVSP). Finally, the associations with HRV variables were tested using linear regression analysis. Genotyped data were used for rs37369 in LURIC. For all other SNPs and analyses, imputed data were used. Imputation quality parameters and minor allele frequencies for AGXT2 and SLC25A45 SNPs are provided in Supplementary material online, Table S2 .
Results

Genome-wide association studies for dimethylarginines and their ratio
We carried out GWA meta-analyses on ADMA, SDMA, and their ratio using data from the YFS and LURIC populations, involving a total of 5110 individuals of European ancestry. The strongest associations for each locus from the meta-analyses are summarized in Table 1 , with an index SNP representing the most significant association labelled for each independent signal. Across the genome, the most significant association for ADMA levels (P ¼ 1.4 × 10
240
) was on chromosome 1p22 harbouring DDAH1, which encodes the key regulatory enzyme of ADMA metabolism DDAH. The most significant signal for SDMA levels (P ¼ 1.4 × 10
) was on chromosome 5p13 at rs37369 (V140I) in the coding sequence of alanine-glyoxylate aminotransferase 2 (AGXT2). Another genome-wide significant signal for SDMA levels (P ¼ 2.5 × 10
210
) was identified in the coding sequence of a mitochondrial carrier protein SLC25A45 at rs34400381 (R285C). A list of suggestive signals for each trait not reaching genomewide significance is provided in Supplementary material online, Tables S4 and S5.
Fine-mapping of the AGXT2 region Next, we fine-mapped the newly identified AGXT2 region showing the strongest association with SDMA for additional independent signals using sequential conditional analysis. Of the methylarginine traits, SDMA was used as an outcome variable in this analysis, because it showed the strongest association with AGXT2 variants in the original meta-analysis. Interestingly, another independent genome-wide significant association was pinpointed at rs16899974 (V498L) when conditioning on the top SNP at rs37369 (V140I) (Figure 2A and B) . In the next step, when adjusting for the two missense mutations (rs37369 and rs16899974), a number of intronic variants showed significant association (P , 10 24 ) with SDMA after correcting for multiple testing in the AGXT2 region ( Figure 2C) . No other informative (P , 10 24 ) intronic or coding sequence AGXT2 variants were identified when further adjusting for the top intronic variant rs13165070 ( Figure 2D ).
Association of non-synonymous AGXT2 variants with heart rate variability in young adults (Young Finns Study)
The SDMA decreasing alleles of the studied AGXT2-coding variants were associated with an increase in the ratio between LF and HF spectral components of the short-term HRV in the YFS ( Table 2 ). The association was especially marked between the novel non-synonymous rs16899974 (V498L) variant and the LF/HF ratio (P ¼ 0.00047). None of the variants showed an association with the LF component (always P . 0.20). Instead, rs16899974 (V498L) variant showed a significant association (P ¼ 0.028) with the HF component (estimate of vagal tone). The non-synonymous SLC25A45 rs34400381 (R285C) variant was not associated with the LF/HF component (P ¼ 0.39), but the SDMA decreasing allele (G) was associated with a decrease in the resting mean heart rate during the HRV measurements independent of the LF/HF ratio ( Table 2) . Further adjustment for serum ADMA or SDMA levels did not change our results.
Associations between non-synonymous AGXT2 and SLC25A45 variants with mortality in Ludwigshafen Risk and Cardiovascular Health
Finally, we investigated whether the non-synonymous AGXT2-and SLC25A45-coding variants independently associated with AGXT2 substrate levels could also predict mortality among patients referred for coronary angiography. None of the studied non-synonymous AGXT2 or SLC25A45 SNPs were associated with all-cause or cardiovascular mortality (always P . 0.05). However, the SDMA decreasing major allele (G) of the SLC25A45 polymorphism (rs34400381, R285C) was associated with an increased risk for SCD with per allele HR of 13.0 (95% CI 1.54 -110, P ¼ 0.018). The two nonsynonymous AGXT2 variants were not associated with SCD in the whole study population. However, both variants showed a significant interaction with LVSP on SCD ( Table 3) . AGXT2 rs16899974 (V498L) showed a nominally significant associated with SCD in the low LVSP group (P ¼ 0.021), whereas there was a trend towards an association for rs37369 (P ¼ 0.10). Analogously to the association for the SLC25A45 variant (R285C), the SDMA decreasing alleles were associated with an increased risk for SCD. No associations were observed between the AGXT2 variants and SCD in the high LVSP group (all P . 0.20), and there was no significant interaction between SLC25A45 rs34400381 and the LVSP status on SCD (P ¼ 0.63). Additional adjustments for circulating ADMA or SDMA did not materially change our results.
Discussion
We report the first GWAS results on circulating ADMA and SDMA levels based on meta-analyses of 5110 individuals of European ancestry, and provide strong evidence that two common nonsynonymous-coding variants in AGXT2 and one non-synonymouscoding variant in SLC25A45 (R285C) are independently associated with circulating SDMA levels. Moreover, we document that the nonsynonymous AGXT2 and SLC25A45 variants showed associations with the LF/HF component of spectral HRV and resting heart rate in young adults, respectively. The polymorphism (rs37369) with the strongest association with circulating SDMA codes for a non-synonymous valine-to-isoleucine (V140I) substitution in the AGXT2 protein. Another non-synomyous AGXT2 rs16899974 (V498L) SNP and a number of intronic variants were also associated independently with SDMA levels. The lead intronic variant (rs13165070) identified in the conditional analysis is in a high linkage disequilibrium (r 2 ¼ 0.9) with intronic rs10521021 that has been previously associated with AGXT2 mRNA levels in the human liver. 21 The T allele of rs37369 is associated with both increased circulating SDMA levels in the present study and increased levels of urinary 3-aminoisobutyrate (BAIB) metabolite. 22 These results together refer to the possibility that the two novel non-synomyous AGXT2 variants may contribute to plasma SDMA levelsthrough the enzymatic decomposition of SDMA in the kidneys. Indeed, AGXT2 Chr., chromosome; position, variant position in NCBI human build 37; EA and NEA, effect allele and non-effect allele; EAF, effect allele frequency; CDS, coding sequence; b, effect size in standard deviations per copy of the effect allele, ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine.
expression in the kidney has recently been shown to be inversely correlated with both circulating ADMA and SDMA levels in humans.
11
SDMA is transaminated to a-keto-d-(N,N ′ -dimethylguanidino)valeric acid (DMGV ′ ) by AGXT2. 23 Our findings support the hypothesis that this mitochondrial 24 AGXT2-related pathway can effectively metabolize SDMA in humans. Moreover, measurable quantities of Table 2 Associations between non-synonomyous AGXT2 and SLC25A45 variants with symmetric dimethylarginine, heart rate variability, and resting heart rate SNP Gene Effect allele EAF (%) GWAS meta-analysis (n 5 5110)
Young Finns (n 5 1723) Per effect allele b (SE) from conditional linear regressions. Effect alleles are SDMA decreasing alleles from the GWAS meta-analysis. Models for the ln-transformed LF/HF component of short-term HRV are adjusted for age, sex, and heart rate. Models for the mean heart rate are adjusted for age, sex, and lnLF/HF. EAF, effect allele frequency; HR, heart rate; b.p.m., beats per minute; SE, standard error; SNP, single-nucleotide polymorphisms; SDMA, symmetric dimethylarginine; LF/HF, the ratio between the low-and high-frequency spectral components of heart rate variability.
a-keto-d-(N,N-dimethylguanidino)valeric acid (DMGV), the transamination product of ADMA by AGXT2, was recently reported being present in human plasma and urine. 25 We observed a genome-wide significant association for SDMA at rs34400381 (R285C) in SLC25A45 encoding a mitochondrial innermembrane transporter protein. Interestingly, SLC25A45 has the same intracellular localization than AGXT2, although its function is not well known. 26 The association is a highly genome-wide significant in the YFS (P ¼ 2.4 × 10 29 ), but only nominally significant in LURIC (P ¼ 0.026). This association clearly needs replication in an independent population.
Our data suggests that non-synonymous AGXT2 variants may have an effect on the autonomic balance mainly by modulating the vagal tone, because AGXT2 rs16899974 was associated with both the LF/ HF ratio and the vagal component HF of HRV alone. The physiological interpretation of LF/HF is not straightforward. The LF component was observed to be correlated with baroreflex function. 27 Moreover, both HF and LF have been shown to be reduced by atropine administration, indicating that both spectral components of HRV are under vagal control, 28 in line with the idea that under resting conditions variations in the heart rate are largely dependent on vagal modulation. 29 Nevertheless, increased LF/HF and decreased HF have been previously associated with increased prevalence of the metabolic syndrome in the YFS cohort. 30 Moreover, decreased HRV appears to be associated with hypertension, dyslipidaemia, impaired glucose metabolism, increased ventricular arrhythmias, and mortality. 31 -35 In the present study, we also showed that a non-synonymous SLC25A45 variant (R285C) was associated with a decreased resting heart rate during the HRV measurements, but not with HRV indices. The observation that the adjustment for circulating methylarginine levels did not change the results suggests that the associations between the AGXT2-and SLC25A45-coding variants and heart rate regulation could be mediated through transamination of other AGXT2 substrates than methylarginines. Although further studies are needed to understand the molecular mechanisms underlying the associations between heart rate regulation and non-synonymous variants within AGXT2 and SLC25A45, it is tempting to speculate that transamination activity of AGXT2 on g-aminobutyric acid isomers glycine and/or b-aminoisobutyric acid (BAIB), a partial glycine receptor agonist 36 could play a role explaining the associations. The striking association of AGXT2 rs37369 with urinary BAIB levels 22 and the presence of glycinergic synaptic inputs to cardiac vagal neurons in the brainstem nuclei 37 support this hypothesis.
None of the genome-wide significant variants were associated with cardiovascular or overall mortality. Interestingly, the AGXT2 substrate (SDMA) decreasing major allele (G) of the nonsynonymous SLC25A45 (R285C) variant was associated with an increased risk for SCD in the whole LURIC population independent of circulation methylarginine levels. However, this association should be interpreted with conscious due to the moderate imputation quality for the variant (Rsq¼ 0.43). Moreover, we observed significant interactions between the pressure creation capacity of the left ventricle and the two non-synonymous AGXT2 variants on SCD. We used LVSP to quantify the degree of the systolic dysfunction and heart failure. Both the increased sympathic drive 38 and the parasympathic withdrawal 39 are integral components of congestive heart failure. It has been known for decades that sympathetic activation can trigger fatal ventricular arrhythmias, whereas vagal activity may exert a protective effect. 38 Interestingly, the HF HRV decreasing major allele (C) of rs16899974 was associated with an increased risk for SCD in patients with impaired systolic function, but not in those with preserved LVSP. Although the AGXT2 substrate levels decreasing alleles of these variants are consistently associated with an increased risk for SCD, these results should be considered as explanatory and a replication in an independent population is warranted. Based on our results, it may be worth investigating whether AGXT22/2 animals have altered vagal tone compared with wildtype animals, and whether they are protected against ventricular arrhythmia in an experimental model of myocardial infarction (MI)-induced systolic heart failure. The associations with the HRV parameters and SCD should also be investigated in an independent population of MI and heart failure patients.
The present study has several strengths and limitations that warrant consideration. The strengths include large, well-characterized cohorts, the prospective design, and long-term follow-up with prospectively adjudicated SCD cases. The potential limitations include the possibility of some degree of misclassification of SCD cases. However, this kind of bias is likely to lead to an underestimation rather than an overestimation of the true genetic effects. Moreover, the generalizability of the SCD association with the general population and other ethnic groups may be limited. Finally, although we attempted to adjust for all relevant covariates, we could not rule out the possibility of residual confounding. In summary, our data clearly indicate that two coding sequences SNPs rs37369 (V140I) and rs16899974 (V498L) in AGXT2 are associated with circulating SDMA levels in two large cohorts of healthy adults and patients referred to coronary angiography, supporting the idea that AGXT2 has a physiological role in the SDMA metabolism in humans. The two non-synomyous AGXT2 variants showed associations with the LF/HF component of spectral HRV, whereas the novel non-synomyous SLC25A45 variant was associated with the resting heart rate in young adults. AGXT2 and SLC25A45 may have unanticipated roles in the regulation of autonomic balance and heart rate in health and disease.
